A practical reference on gastric juice protein: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-21 and is reviewed periodically as new material appears.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
=== Graphene superlattices === Periodically stacked graphene and its insulating isomorph provide a fascinating structural element in implementing highly functional superlattices at the atomic scale, which offers possibilities for designing nanoelectronic and photonic devices. Various types of superlattices can be obtained by stacking graphene and its related forms. The energy band in layer-stacked superlattices is found to be more sensitive to the barrier width than that in conventional III–V semiconductor superlattices. When adding more than one atomic layer to the barrier in each period, the coupling of electronic wavefunctions in neighboring potential wells can be significantly reduced, which leads to the degeneration of continuous subbands into quantized energy levels. When varying the well width, the energy levels in the potential wells along the L-M direction behave distinctly from those along the K-H direction. A superlattice corresponds to a periodic or quasi-periodic arrangement of different materials and can be described by a superlattice period which confers a new translational symmetry to the system, impacting their phonon dispersions and subsequently their thermal transport properties. Recently, uniform monolayer graphene-hBN structures have been successfully synthesized via lithography patterning coupled with chemical vapor deposition (CVD). Furthermore, superlattices of graphene-HBN are ideal model systems for the realization and understanding of coherent (wave-like) and incoherent (particle-like) phonon thermal transport.
=== Resistant gram negative bacteria === Investigators in the National Human Genome Research Institute and the NIH Clinical Center have used advanced DNA sequencing methods to characterize carbapenem-resistant enterobacteriaceae in hospitalized patients. They tracked a cluster of infections in hospitalized patients, then more recently, Frank's laboratory conducted a two-year follow-up study to understand the possible spread of the resistant genes between bacteria on plasmids. To further investigate the mechanisms used by bacteria to spread resistance, Frank's research program examined the frequency of horizontal gene transfer among species, using bacterial isolates from two hospitals. Most conjugation studies use a lab strain of E. coli, typically under narrow conditions. Given that conjugation is influenced by multiple factors, we sought to perform a systematic analysis of blaKPC encoding plasmids transfer into multiple species. The efficiency of conjugation into enterobacteriaceae patient isolates and a common lab cloning E. coli strain ranged widely from high rates of 10-2 or 10-3 CFU transconjugants/CFU recipients to undetectable, without a clear correlation with the pattern of spread suggested during two hospital outbreaks. In vitro models may not faithfully predict plasmid mobilization until we better understand the most important variables affecting conjugation efficiency.
=== President and Past Presidents (since 1953) === 2022–2024 Julia Laskin 2020–2022 Susan Richardson 2016–2018 Vicki Wysocki 2014–2016 Jennifer Brodbelt 2012–2014 Susan Weintraub 2006–2008 Barbara S. Larsen 2002–2004 Catherine E. Costello 1996–1998 Veronica M. Bierbaum 1982–1984 Catherine Fenselau
== Pharmacokinetics == A small amount of sulfanilamide is absorbed following topical application or when administered as a vaginal cream or suppository (through the vaginal mucosa). It is metabolized by acetylation like other sulfonamides and excreted through the urine.
Sources: en.wikipedia.org
The choroid plexus regulates the production and composition of cerebrospinal fluid (CSF), that provides the protective buoyancy for the brain. CSF acts as a medium for the glymphatic filtration system that facilitates the removal of metabolic waste from the brain, and the exchange of biomolecules and xenobiotics into and out of the brain. In this way the choroid plexus has a very important role in helping to maintain the delicate extracellular environment required by the brain to function optimally. The choroid plexus is also a major source of transferrin secretion that plays a part in iron homeostasis in the brain.
Atomic nitrogen, also known as active nitrogen, is highly reactive, being a triradical with three unpaired electrons. Free nitrogen atoms easily react with most elements to form nitrides, and even when two free nitrogen atoms collide to produce an excited N2 molecule, they may release so much energy on collision with even such stable molecules as carbon dioxide and water to cause homolytic fission into radicals such as CO and O or OH and H. Atomic nitrogen is prepared by passing an electric discharge through nitrogen gas at 0.1–2 mmHg, which produces atomic nitrogen along with a peach-yellow emission that fades slowly as an afterglow for several minutes even after the discharge terminates. Given the great reactivity of atomic nitrogen, elemental nitrogen usually occurs as molecular N2, dinitrogen. This molecule is a colourless, odourless, and tasteless diamagnetic gas at standard conditions: it melts at −210 °C and boils at −196 °C. Dinitrogen is mostly unreactive at room temperature, but it will nevertheless react with lithium metal and some transition metal complexes. This is due to its bonding, which is unique among the diatomic elements at standard conditions in that it has an N≡N triple bond. Triple bonds have short bond lengths (in this case, 109.76 pm) and high dissociation energies (in this case, 945.41 kJ/mol), and are thus very strong, explaining dinitrogen's low level of chemical reactivity.
=== Other bodies in exile === Other Grand Lodges were created for the Cuban exile community, including the United Grand Lodge of the Antilles (Spanish: Gran Logia Unida de las Antillas), and the Most Serene Grand Lodge (Spanish: Serenisima Gran Logia), and the Cuba First Federation of Cuban Masons in Exile (Spanish: Federacion de Masones Cubanos Cuba Primero).
The signal is detected by a P2X receptor; these receptors occur across the animal kingdom in phyla including sponges, cnidaria, placozoa, mollusca, arthropoda, and chordata, and in both fungi and green plants. Such sharing between eukaryote groups implies that these damage response mechanisms are ancient and have been conserved in evolution. Thibaut Brunet and Detlev Arendt propose that the last eukaryotic common ancestor (LECA) possessed a calcium-based wound healing response. They argue that the mechanism's purpose was to detect and heal a potentially fatal opening in the cell membrane. They propose that it worked by detecting an inflow of calcium ions, which provoked a contraction in muscle-like actomyosin proteins. This in turn caused vesicles to fuse with the cell membrane (exocytosis), healing the opening and preventing the cell from splitting open.
Sinokrot Holding is the largest family-owned business group in Palestine, established in 1982. It is based in Ramallah, operating in 20,000 m2 of buildings with 350 employees. The company sells from more than 4,000 outlets. The chairman, Mazen Sinokrot, who was a Minister of National Economy until March 2006, as well as Chairman of the Board for the Palestine Standards Institute, Palestine Investment and Promotion Agency, and Palestine Industrial Zones and Free Zones Authority.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.